

Appln. No. 09/537,858  
Supplemental Amdt. dated January 12, 2005  
Reply to Office action of April 15, 2004

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Pending Claims Appln. 09/537,858 (PROOST1)

1-24 (Canceled)

25 (Currently Amended). An isolated amino-terminally truncated RANTES polypeptide consisting of residues 3-68 of a RANTES polypeptide according to SEQ ID NO:1, wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 and has the ability to inhibit monocyte cell chemotaxis towards ~~CC chemokines~~ MCP-3, MIP-1 $\alpha$  and MIP-1 $\beta$ , and ~~the ability to retain the capacity of intact RANTES to bind~~ has CCR5 agonistic activity.

26-27 (Canceled)

28 (Previously Presented). The isolated amino-terminally truncated RANTES of claim 25, wherein the truncated RANTES polypeptide is in glycosylated form.

29 (Previously Presented). A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to claim 25, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.

Appln. No. 09/537,858

Supplemental Amdt. dated January 12, 2005

Reply to Office action of April 15, 2004

30 (Previously Presented). The pharmaceutical composition according to claim 29, wherein the isolated truncated RANTES polypeptide is in glycosylated form.

31-35 (Cancelled)